LONDON: Abcam plc, a global leader in the supply of life science research tools, announced the pricing of its offering of 8.945 million American Depositary Shares (ADSs) at a price of $17.50 per ADS, for aggregate proceeds of approximately $156.5 million.
Each ADS offered represents one ordinary share of Abcam. The ADSs are being offered in a registered public offering in the United States.
In addition, Abcam has granted the underwriters a 30-day option to purchase up to an additional 1.341 million ADSs on the same terms and conditions.
The closing of the Offering is expected to occur on October 26, 2020, subject to customary closing conditions.
Abcam’s ordinary shares are admitted to trading on the AIM market of the London Stock Exchange under the symbol “ABC.” The ADSs have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the symbol “ABCM” on October 22, 2020.
Morgan Stanley and BofA Securities are acting as the lead book-running managers for the Offering. SVB Leerink is acting as a book-running manager, and Lazard and William Blair are acting as co-managers.